Standardised case definitions for adverse events following immunisation - Authors' reply

Comment

Timo Vesikari. Lancet. 2013.

. 2013 Jun 29;381(9885):2251.

doi: 10.1016/S0140-6736(13)61478-6.

No abstract available

Comment on

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Vesikari T, et al. Lancet. 2013 Mar 9;381(9869):825-35. doi: 10.1016/S0140-6736(12)61961-8. Lancet. 2013. PMID: 23324563 Clinical Trial.
Standardised case definitions for adverse events following immunisation.
Heininger U. Heininger U. Lancet. 2013 Jun 29;381(9885):2250-1. doi: 10.1016/S0140-6736(13)61477-4. Lancet. 2013. PMID: 23809555 No abstract available.